Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.
OBJECTIVE
To explore characteristic gene mutations in nonsmall-cell lung carcinoma (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) and sensitivity to Tarceva therapy; to observe the efficacy and safety of Tarceva therapy for NSCLC patients with wild-type EGFR.


METHODS
NSCLC patients with wild-type EGFR and KRAS were selected. Their tumor specimens were assessed for mutations in seven key genes in pathways downstream of EGFR, including HRAS, NRAS, BRAF, PIK3CA, AKT1, MEK1, and PTEN. Then the patients were subjected to Tarceva therapy to explore the relationship between curative effects and any gene mutations.


RESULTS
Among 10 cases, one NRAS mutation was detected in one patient who was resistant to Tarceva, and no mutations were detected in the other patients. Seven cases responded to Tarceva; 1 case obtained partial relief, and 6 cases were in stable condition.


CONCLUSIONS
Patients with wild-type EGFR can also benefit from Tarceva therapy. However, an association between Tarceva therapy sensitivity and mutations in genes downstream of EGFR was not detected.
Yan
Y
Cui
Jie
J
Xu
Liang
L
Xin
Ye
Y
Tian
Zhongli
Z
Zhan
Department of Senior Ward, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, China.
Daliang
D
Qi
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors